At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 1, 2026 at 09:45 ET
Septerna announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator, showing robust, dose-dependent inhibition of mast cell activation with a favorable safety profile and pharmacokinetics supporting once-daily dosing. The company plans to advance SEP-631 into a Phase 2b trial for chronic spontaneous urticaria (CSU) in the second half of 2026 and explore additional mast cell-driven indications.
- SEP-631 demonstrated complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once daily.
- The drug was well-tolerated with an adverse event profile comparable to placebo and no serious adverse events.
- Pharmacokinetic data show a half-life of ~24 hours, supporting once-daily oral dosing without food restrictions.
- Phase 2b trial in chronic spontaneous urticaria (CSU) planned for second half of 2026, pending toxicology study completion.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access